Clinical Trial Update: Impact of Valganciclovir on Severe IRIS-Kaposi Sarcoma Mortality: an Open-label, Parallel, Randomized Controlled-trial. [Phase 2]

View source ↗

Summary

A Phase 2 open-label randomized trial evaluating valganciclovir for reducing mortality in severe IRIS-Kaposi sarcoma; completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Kaposi Sarcoma

Drugs mentioned

• Valganciclovir (Valganciclovir)

Snippet

Sponsor: National Institute of Cancerología | Conditions: Kaposi Sarcoma, Human Immunodeficiency Virus | Phase 2 | Status: COMPLETED | Results posted: 2022-01-27